Involving Reactive Oxygen Species Tumors through a Caspase-Independent Mechanism Proton Pump Inhibitors Induce Apoptosis of Human B-Cell

Proton pumps like the vacuolar-type H ATPase (V-ATPase) are involved in the control of cellular pH in normal and tumor cells. Treatment with proton pump inhibitors (PPI) induces sensitization of cancer cells to chemotherapeutics via modifications of cellular pH gradients. It is also known that low pH is the most suitable condition for a full PPI activation. Here, we tested whether PPI treatment in unbuffered culture conditions could affect survival and proliferation of human B-cell tumors. First, we showed that PPI treatment increased the sensitivity to vinblastine of a pre-B acute lymphoblastic leukemia (ALL) cell line. PPI, per se , induced a dose-dependent inhibition of proliferation of tumor B cells, which was associated with a doseand time-dependent apoptotic-like cytotoxicity in B-cell lines and leukemic cells from patients with pre-B ALL. The effect of PPI was mediated by a very early production of reactive oxygen species (ROS), that preceded alkalinization of lysosomal pH, lysosomal membrane permeabilization, and cytosol acidification, suggesting an early destabilization of the acidic vesicular compartment. Lysosomal alterations were followed by mitochondrial membrane depolarization, release of cytochrome c , chromatin condensation, and caspase activation. However, inhibition of caspase activity did not affect PPI-induced cell death, whereas specific inhibition of ROS by an antioxidant (N-acetylcysteine) significantly delayed cell death and protected both lysosomal and mitochondrial membranes. The proapoptotic activity of PPI was consistent with a clear inhibition of tumor growth following PPI treatment of B-cell lymphoma in severe combined immunodeficient mice. This study further supports the importance of acidity and pH gradients in tumor cell homeostasis and suggests new therapeutic approaches for human B-cell tumors based on PPI. [Cancer Res 2007;67(11):5408–17]

[1]  K. Öllinger,et al.  Cytosolic acidification and lysosomal alkalinization during TNF-α induced apoptosis in U937 cells , 2006, Apoptosis.

[2]  Licia Rivoltini,et al.  Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. , 2006, Cancer research.

[3]  G. Winberg,et al.  Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. , 2005, Experimental hematology.

[4]  S. Fais,et al.  Tumor acidity, chemoresistance and proton pump inhibitors. , 2005, Future oncology.

[5]  Guido Kroemer,et al.  Lysosomes and autophagy in cell death control , 2005, Nature Reviews Cancer.

[6]  A. Cossarizza,et al.  Characterization of cells with different mitochondrial membrane potential during apoptosis , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  Jinjun Li,et al.  The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. , 2005, Cancer research.

[8]  S. Fais,et al.  Proton pump inhibitors may reduce tumour resistance , 2005, Expert opinion on pharmacotherapy.

[9]  F. Lozupone,et al.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. , 2004, Journal of the National Cancer Institute.

[10]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[11]  E. Ayroldi,et al.  Omeprazole Induces Apoptosis in Jurkat Cells , 2004, International journal of immunopathology and pharmacology.

[12]  L. Swinnen,et al.  Treatment advances in adult Burkitt lymphoma and leukemia , 2004, Current opinion in oncology.

[13]  K. Bakunts,et al.  Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. , 2004, American journal of physiology. Cell physiology.

[14]  V. Dawson,et al.  Role of AIF in caspase-dependent and caspase-independent cell death , 2004, Oncogene.

[15]  H. Uramoto,et al.  Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. , 2003, Cancer treatment reviews.

[16]  M. Solaiyappan,et al.  Extracellular acidification alters lysosomal trafficking in human breast cancer cells. , 2003, Neoplasia.

[17]  G. Der An overview of proton pump inhibitors. , 2003, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[18]  Shigenori Tamaki,et al.  Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. , 2003, Journal of biochemistry.

[19]  E. T. Gawlinski,et al.  The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. , 2003, Cancer research.

[20]  G. Kroemer,et al.  Lysosomal Membrane Permeabilization Induces Cell Death in a Mitochondrion-dependent Fashion , 2003, The Journal of experimental medicine.

[21]  A. J. Mukkada,et al.  Antileishmanial Activity of the Antiulcer Agent Omeprazole , 2002, Antimicrobial Agents and Chemotherapy.

[22]  T. Nishi,et al.  The vacuolar (H+)-ATPases — nature's most versatile proton pumps , 2002, Nature Reviews Molecular Cell Biology.

[23]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[24]  Toshitaka Nakamura,et al.  Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance , 2001, International journal of cancer.

[25]  J. Lakowicz,et al.  Fluorescence lifetime characterization of novel low-pH probes. , 2001, Analytical biochemistry.

[26]  R. Chandraratna,et al.  Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells , 2001, Cell Death and Differentiation.

[27]  J. Uhr,et al.  A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Chessells Recent advances in management of acute leukaemia , 2000, Archives of disease in childhood.

[29]  J. Horn,et al.  The proton-pump inhibitors: similarities and differences. , 2000, Clinical therapeutics.

[30]  O. Garden,et al.  Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. , 2000, Blood.

[31]  J. Cleveland,et al.  The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. , 1999, Cancer research.

[32]  R. Gillies,et al.  pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. , 1999, Biochemical pharmacology.

[33]  T. Kühler,et al.  Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp , 1997, Antimicrobial agents and chemotherapy.

[34]  T. Nishihara,et al.  Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death. , 1995, Biochemical and biophysical research communications.

[35]  M. Katashima,et al.  Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[36]  P. Boura,et al.  In vivo effect of omeprazole on HLA-DR expression and the monocyte-macrophage function in patients with duodenal ulcer disease. , 1994, Immunopharmacology and immunotoxicology.

[37]  J. Verbavatz,et al.  H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. , 1994, The American journal of physiology.

[38]  Y. Moriyama,et al.  Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase. , 1993, Biochemical and biophysical research communications.

[39]  R. Gillies,et al.  Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. , 1993, The American journal of physiology.

[40]  M. Fukuda,et al.  Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. , 1992, The Journal of biological chemistry.

[41]  D. Marquardt,et al.  Involvement of vacuolar H(+)-adenosine triphosphatase activity in multidrug resistance in HL60 cells. , 1991, Journal of the National Cancer Institute.

[42]  K. Väänänen,et al.  Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. , 1991, Biochimica et biophysica acta.

[43]  J. Tuukkanen,et al.  Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts , 1990, The Journal of cell biology.

[44]  Defeng Luo,et al.  Plasmalemmal vacuolar-type H+-ATPase in cancer biology , 2007, Cell Biochemistry and Biophysics.

[45]  C. Nilsson,et al.  Analysis of cytosolic and lysosomal pH in apoptotic cells by flow cytometry. , 2003, Methods in cell science : an official journal of the Society for In Vitro Biology.

[46]  P. Engström,et al.  Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. , 2002, Pediatrics.

[47]  ©1999 Cancer Research Campaign Article no. bjoc.1998.0455 Enhancement of chemotherapy by manipulation of tumour pH , 2022 .